| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11938-003-0010-0 |
| P698 | PubMed publication ID | 12628068 |
| P2093 | author name string | Cynthia Levy | |
| Keith D. Lindor | |||
| P2860 | cites work | Cholangiocarcinoma complicating primary sclerosing cholangitis | Q24540424 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Effects of Clofibrate in Primary Biliary Cirrhosis Hypercholesterolemia and Gallstones | Q28340259 | ||
| Immunopathogenesis of primary biliary cirrhosis | Q33337756 | ||
| The pathogenesis and treatment of pruritus and fatigue in patients with PBC. | Q33694855 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Etiology and natural history of primary sclerosing cholangitis | Q33831881 | ||
| Surgical treatment for primary sclerosing cholangitis | Q33831898 | ||
| Hepatic and extrahepatic malignancies in primary sclerosing cholangitis | Q33957644 | ||
| Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 | ||
| Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice | Q34223451 | ||
| Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial | Q34315230 | ||
| Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. | Q34330984 | ||
| Fat-soluble vitamin levels in patients with primary biliary cirrhosis | Q34379099 | ||
| Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis | Q34409622 | ||
| Recurrence of primary sclerosing cholangitis after liver transplantation | Q34713191 | ||
| Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years | Q34932835 | ||
| Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment | Q35358467 | ||
| Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron | Q39476222 | ||
| Epidemiology and natural history of primary biliary cirrhosis in a US community | Q40735092 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis | Q43433946 | ||
| High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis | Q43618408 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future | Q43623767 | ||
| Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. | Q43734578 | ||
| A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis | Q43770466 | ||
| Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy | Q43865110 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers | Q43954071 | ||
| Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? | Q43988210 | ||
| The demography of primary biliary cirrhosis in Ontario, Canada | Q44439436 | ||
| Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis | Q44627887 | ||
| Risk factors for primary biliary cirrhosis in a cohort of patients from the united states | Q44933098 | ||
| Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis | Q45103515 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Primary sclerosing cholangitis: surgical options, prognostic variables and outcome | Q50155200 | ||
| Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. | Q50636283 | ||
| Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. | Q50636830 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. | Q50684179 | ||
| A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
| Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. | Q52067430 | ||
| Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? | Q53569336 | ||
| Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. | Q54032405 | ||
| Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. | Q55035486 | ||
| Natural history and prognostic variables in primary sclerosing cholangitis | Q67915561 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation | Q71057922 | ||
| Treatment of cholestatic itching in primary biliary cirrhosis with ondansetron | Q71450220 | ||
| Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study | Q71598528 | ||
| Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis | Q71605603 | ||
| Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis | Q71713603 | ||
| The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study | Q71739390 | ||
| A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group | Q71748735 | ||
| Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression | Q71949347 | ||
| A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis | Q71995039 | ||
| Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone | Q72227193 | ||
| Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis | Q72351251 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Paradoxical Elevation of Serum Cholesterol by Clofibrate in Patients with Primary Biliary Cirrhosis | Q72467519 | ||
| Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period | Q72503309 | ||
| Primary sclerosing cholangitis: liver transplantation or biliary surgery | Q72522531 | ||
| Endoscopic therapy of sclerosing cholangitis | Q72590521 | ||
| Primary sclerosing cholangitis | Q72596376 | ||
| Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis | Q72736523 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis | Q73090688 | ||
| Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid | Q73122828 | ||
| Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study | Q73167014 | ||
| Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study | Q73363202 | ||
| Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | Q73401694 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis | Q73497916 | ||
| The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone | Q73574823 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women | Q73911971 | ||
| Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer | Q73939619 | ||
| Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis | Q73979498 | ||
| Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis | Q74529900 | ||
| Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy | Q77113445 | ||
| Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry | Q77150135 | ||
| Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study | Q77619532 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis | Q77943870 | ||
| Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol | Q78039881 | ||
| P433 | issue | 2 | |
| P921 | main subject | ascending cholangitis | Q603644 |
| primary sclerosing cholangitis | Q1058608 | ||
| primary biliary cholangitis | Q1072420 | ||
| P304 | page(s) | 93-103 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Current treatment options in gastroenterology | Q27714745 |
| P1476 | title | Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis | |
| P478 | volume | 6 |
| Q35768888 | Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence |
| Q37587269 | Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations |
| Q34382536 | Primary sclerosing cholangitis: updates in diagnosis and therapy |
Search more.